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iAbstract
Soluble TLR2 levels are elevated in infective and inflammatory conditions, but its
diagnostic value with sepsis-induced multi-organ failure has not been evaluated. 37
patients with a diagnosis of severe sepsis/septic shock (sepsis) and 27 patients with
organ failure without infection (SIRS) were studied. Median (IQR) plasma sTLR2 levels
were 2.7 ng/ml (1.4–6.1) in sepsis and 0.6 ng/ml (0.4–0.9) in SIRS p < 0.001. sTLR2
showed good diagnostic value for sepsis at cut-off of 1.0 ng/ml, AUC:0.959. We
report the ability of sTLR2 levels to discriminate between sepsis and SIRS within 12 h
of ICU admission in patients with multi-organ failure.Findings
The diagnosis of sepsis in ICU patients with organ failure is fraught with difficulty
since both clinical signs and current diagnostic tests may be equivocal. Source control
and timely antibiotic administration are crucial; thus, diagnostic tests that might enable
early exclusion or positive identification of an infective etiology of critical illness are
the focus of intensive research [1].
Toll-like receptor 2 (TLR2) is a member of a family of immune receptors which
trigger pro-inflammatory responses following recognition of a range of microorganisms
such as bacteria, viruses, and fungi. TLR2 is mainly expressed by myeloid cells and a
soluble form (sTLR2), capable of down-modulating TLR-mediated pro-inflammatory
responses, is released in response to microbial challenges [2]. Plasma levels of sTLR2
are elevated in a number of infective and inflammatory conditions [3] but its diagnostic
value in ICU patients with sepsis-induced multi-organ failure has not been evaluated.
Following ethical approval by the South East Wales Research Ethics Committee
(reference number 10WSE/421, June 2011) registration with the UK Clinical Research
Network (UKCRN; cellular and biochemical investigations in sepsis, ID 11231) and
written consent, 37 patients presenting to the Royal Glamorgan Hospital 10-bedded
mixed medical/surgical ICU between January 2011 and March 2014 with a diagnosis of
severe sepsis or septic shock according to the ESICM/SCCM consensus criteria [4]
were enrolled within 24 h of the presumed onset of their illness, together with a cohort
of 27 patients with organ failure due to dysregulated host response of non-infectiveThe Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
icense (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
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more SIRS criteria, had documented organ dysfunction, but were not treated with anti-
microbials for known or presumed infection. Blood was drawn within 12 h of ICU
admission and plasma sTLR2 and C-reactive protein levels were determined by ELISA
methods following the manufacturer’s instructions (R&D Systems, Minneapolis, MN,
sTLR2 in normal serum: 0.575 ± 0.140 ng/ml; range 0.296–0.880).
For statistical analysis, chi-square test and Mann-Whitney U test—when the Kruskal-
Wallis test rejected the null hypothesis of no differences between medians—was used
as appropriate. We assessed correlations between parameters using the Spearman Rho’s
correlation test. A result was considered to be significant at p < 0.05. Receiver operating
characteristic (ROC) curves were plotted and the respective areas under the curve were
calculated. Statistics were performed using the Statistical Program for Social Sciences
(SPSS®) 20.0 software for Mac (Chicago, IL, USA).
Clinical characteristics of the patients in the sepsis and SIRS groups are presented in
Table 1. Five patients in the sepsis group had culture-proven Gram-positive infection
(four blood culture and one sputum), four had Gram-negative infection (all blood
culture), and one had fungal infection (blood culture). Median (interquartile range)
plasma sTLR2 levels were 2.7 ng/ml (1.4–6.1) in patients with severe sepsis and
septic shock and 0.6 ng/ml (0.4–0.9) in patients with SIRS (p < 0.001 by Mann-
Whitney U test, Fig. 1a). With a cut-off value of 1.0 ng/ml, sTLR2 showed good
diagnostic value for sepsis, as it had a sensitivity of 90%, a specificity of 91%, and
an AUC of 0.959 (Fig. 1b).
In this feasibility pilot study, we report the ability of sTLR2 levels to discriminate
between sepsis and SIRS within 12 h of ICU admission in a well-balanced group ofTable 1 Characteristics of patients in the sepsis and SIRS groups
Sepsis n = 37 SIRS n = 27 p value
Age 63 (55–72) 63 (48–69) 0.298
Sex (M/F) 17/20 20/7 0.040
Admission SOFA 16 (14–19) 14 (13–17) 0.080
White cell count (109/L) 15 (11–22) 13 (8–17) 0.169
Mean arterial pressure (mmHg) 78 (67–87) 79 (72–91) 0.445
PEEP (cm H2O) 8 (5–8) 7 (5–9) 0.892
SpO2 (%) 98 (95–100) 99 (98–100) 0.131
FiO2 0.5 (0.4–0.6) 0.4 (0.35–0.5) 0.326
Peak inspiratory pressure (cm H2O) 22 (19–25) 24 (16–29) 0.528
Creatinine (μmol/L) 158 (86–259) 88 (66–168) 0.010
Urea (mmol/L) 13.2 (8.6–18.3) 6.2 (4.2–10) <0.001
Albumin (g/L) 20 (16–25) 31 (22–34) <0.001
CRP (mg/L) 218 (129–340) 84 (40–168) 0.001
ICU stay (days) 10 (5–15) 4 (3–8) 0.016
Ventilated days 5 (2–9) 3 (1–4) 0.133
Shock days 3 (2–4) 0 (0–3) 0.002
Renal support days 0 (0–5) 0 (0–0) 0.011
In-hospital mortality 12 (32%) 11 (41%) 0.142
Data are presented as medians, with the interquartile ranges in brackets. For statistical analysis, Mann-Whitney U test and
chi-square test were used to test differences between the sepsis and SIRS groups
Fig. 1 Individual sTLR2 levels in the sepsis and SIRS groups (a) and receiver operating characteristic curve (ROC)
for the ability of sTLR2 and CRP levels to diagnose sepsis (b). Area under the curve (AUC) for sTLR2 0.959; 95% CI
0.912–1.000; AUC for CRP 0.764; 95% CI 0.635–0.894
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regulatory mechanism to avoid harmful inflammatory responses [2]. The observed
higher levels of plasma sTLR2 in sepsis (irrespective of the causative organism) than in
SIRS patients suggest that this negative feedback mechanism is rapidly and preferen-
tially activated upon infection. Notably, we found that sTLR2 has better specificity and
sensitivity for sepsis than C-reactive protein, the most commonly used marker in the
ICU (Fig. 1b, AUC - sTLR2 0.959; CRP - 0.764). It is encouraging that sTLR2 levels
below 1 ng/mL had good ability to rule out sepsis whether it is secondary to bacterial
or fungal infection within the first 12 h of ICU stay, when clinical parameters and trad-
itional markers of infection are often equivocal. While sTLR2 levels on their own
appear to be good markers of sepsis within the first 12 h of ICU admission, it is likely
that they might perform even better as part of a biomarker panel [5]. Given the small
sample size of our study, these promising findings warrant a larger confirmatory trial
before sTLR2 levels can be introduced in the routine clinical practice.
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